Open this publication in new window or tab >>2025 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]
Oncology drug development remains one of the most challenging domains in pharmaceutical research, marked by high attrition rates, suboptimal dose selection, and limited translatability of preclinical findings, particularly with the emerging therapeutic modalities. Model-informed drug development (MIDD) provides a quantitative paradigm for integrating data across the preclinical-to-clinical continuum, thereby enabling evidence-based decision-making. Within this paradigm, mechanism-based pharmacometric models facilitate a structured MIDD approach by quantitatively capturing the interplay between drug exposure, pharmacological response, disease progression, and adverse events. This thesis leverages such models to address key questions in oncology drug development, informing dose optimisation, biomarker qualification, and therapeutic strategy.
Therapeutic cancer vaccines stimulate the immune system to recognise and eradicate cancer cells. The adaptable drug affinity conjugate (ADAC) platform, in preclinical development, employs a bispecific antibody engineered to bind a pTag–peptide sequence. A novel multiscale semi-mechanistic pharmacokinetic-pharmacodynamic (PKPD) modelling framework was developed to characterise ADAC-induced immune responses and tumour dynamics in inflamed and non-inflamed murine tumour models. Model-based simulations demonstrated that higher pTag binding affinity prolonged peptide residence time and enhanced antitumor activity. UV1, a telomerase-based vaccine, was evaluated in Phase I trials. A mechanistic modelling framework, integrating tumour size, immune response, and survival data, suggested extending maintenance dosing for more sustained tumour shrinkage.
Ibrutinib, a Bruton’s tyrosine kinase inhibitor for chronic lymphocytic leukaemia, is frequently associated with hypertension, often necessitating dose modifications in clinical practice. A novel semi-mechanistic PKPD modelling framework was constructed to delineate the relationships among plasma exposure, leukocyte and lymphocyte dynamics, lymph node and spleen size, and blood pressure. Model-based dose reduction simulations suggested that therapeutic efficacy could be maintained while reducing hypertension risk.
Paclitaxel-induced peripheral neurotoxicity (PIPN) is a common dose-limiting toxicity, with serum neurofilament light chain (sNfL) emerging as a promising neurotoxicity biomarker. A translational integrated plasma-PIPN sites PK model, developed using preclinical data and scaled to humans, was linked to a novel PKPD model describing the relationship between paclitaxel exposure, sNfL, and Total Neuropathy Score–clinical version in breast cancer patients. Model-based landmark analysis highlighted sNfL as a potential predictive biomarker for PIPN severity.
In summary, this thesis demonstrates the utility of mechanism-based pharmacometric modelling in integrating diverse data types into an informative and predictive framework. Through applications spanning diverse therapeutic modalities, this work advances model-based strategies to improve decision-making across the drug development lifecycle.
Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2025. p. 90
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 384
Keywords
pharmacometrics, oncology, model-informed drug development, dose optimisation, pharmacokinetics, pharmacodynamics, biomarkers.
National Category
Pharmaceutical Sciences
Research subject
Pharmaceutical Science
Identifiers
urn:nbn:se:uu:diva-565557 (URN)978-91-513-2574-3 (ISBN)
Public defence
2025-10-16, A1:107a, BMC, Husargatan 3, Uppsala, 09:15 (English)
Opponent
Supervisors
Funder
Swedish Cancer Society, CAN 2017/626, 20 1226 PjF, and 23 2921 Pj
2025-09-252025-08-282025-09-25